Pneumococcal Vaccines
Conditions
Brief summary
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
Detailed description
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels (Low: 1.1 mcg; Mid: 2.2 mcg; or Mixed: 2.2/4.4 mcg) compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
Interventions
BIOLOGICAL24-Valent Pneumococcal Conjugate Vaccine
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
BIOLOGICALPneumococcal 20-valent Conjugate Vaccine
0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
Sponsors
Vaxcyte, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Triple (Participant, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male or female age 65 or older. * Able and willing to complete the informed consent process. * Available for clinical follow-up through the last study visit at 6 months after the study vaccination. * In good general health as determined by medical history, vital signs, physical examination, and clinical judgment of the investigator. Preexisting medical conditions must be stable as defined by no change in treatment at least 6 weeks prior to study participation. * Willing to have blood samples collected, stored indefinitely, and used for research purposes. * Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process.
Exclusion criteria
* Previous pneumococcal disease (either confirmed or by self-reporting). * Previous receipt of a licensed or investigational pneumococcal vaccine. * Receipt of any investigational study product within 30 days prior to enrollment into the study, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study. * Planned or actual administration of any licensed vaccine during the period starting 30 days before enrollment into the study through Day 29. * Physical examination indicating any clinically significant medical condition. * Body Temperature \> 38.0°C (\> 100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescheduled). * Previous or existing diagnosis of HIV, Hepatitis B or Hepatitis C. * History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis. * Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular injections or blood draws. * Any other chronic or clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject or confound evaluation of the study vaccine. * Any medical, psychiatric, or social condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent. * Received blood or blood product (including Immune Globulin IV) within 90 days prior to enrollment into the study. * Received systemic corticosteroids for ≥ 14 consecutive days and has not completed treatment ≤30 days prior to enrollment into the study. * Receiving immunosuppressive therapy. * History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After Vaccination | 1 month after vaccination | Percentage of participants with at least one Treatment Emergent Adverse Event (unsolicited AEs and SAEs) |
| Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | 7 days after vaccination | Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain within 7 days of vaccination |
| Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | 7 days after vaccination | Solicited local reactions included redness/erythema, swelling/induration, and pain at injection site |
| Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | 6 months after vaccination | Percentage of participants with serious adverse events (SAEs) and new onset of chronic illness (NOCIs) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 month after vaccination | The change from baseline to 1 month post-vaccination in the immune response directed against each of the 24 serotypes was evaluated by measuring serotype-specific functional antibody responses with an opsonophagocytic (OPA) assay that assesses the functional capacity of pneumococcal antibodies. |
| 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 1 month after vaccination | The change from baseline to 1 month post-vaccination in the immune response directed against each of the 24 serotypes was evaluated by measuring IgG levels using an IgG multiplexed electrochemoluminescent assay (ECLA). Values below the lower limit of quantitation (LLOQ) were analyzed as 0.5\*LLOQ. Values above the upper limit of quantitation (ULOQ) were analyzed as 1\*ULOQ. |
Countries
United States
Participant flow
Pre-assignment details
230 participants were screened; 21 did not meet eligibility criteria and 2 were excluded for other reasons. 1 participant was randomized to VAX-24 2.2 mcg but was administered and included in the analysis for VAX-24 2.2/4.4 mcg dose. 1 participant in the PCV20 group was lost to follow up at day 1 without any solicited or unsolicited AEs collected. A 66-year-old male did not finish due to sudden cardiac death not considered related to vaccine due to risk factors of hypertension and BMI=47.4
Participants by arm
| Arm | Count |
|---|---|
| VAX-24 Low Dose Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1.
24-Valent Pneumococcal Conjugate Vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 52 |
| VAX-24 Mid Dose Participants will receive a single dose of VAX-24 2.2 mcg administered as an intramuscular injection on Day 1.
24-Valent Pneumococcal Conjugate Vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 52 |
| VAX-24 Mixed Dose Participants will receive a single dose of VAX-24 2.2 mcg/4.4 mcg administered as an intramuscular injection on Day 1.
24-Valent Pneumococcal Conjugate Vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 52 |
| PCV20Group 4 Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
Pneumococcal 20-valent Conjugate Vaccine: 0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1 | 51 |
| Total | 207 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Death | 0 | 1 | 0 | 0 |
| Overall Study | Lost to Follow-up | 1 | 1 | 2 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | VAX-24 Low Dose | Total | PCV20Group 4 | VAX-24 Mixed Dose | VAX-24 Mid Dose |
|---|---|---|---|---|---|
| Age, Continuous | 67.5 Years | 67.0 Years | 67.0 Years | 67.0 Years | 66.5 Years |
| Body Mass Index (kg/m^2) | 27.42 kg/m^2 | 28.82 kg/m^2 | 28.99 kg/m^2 | 29.48 kg/m^2 | 28.98 kg/m^2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 5 Participants | 25 Participants | 8 Participants | 5 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 44 Participants | 174 Participants | 41 Participants | 46 Participants | 43 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants | 8 Participants | 2 Participants | 1 Participants | 2 Participants |
| Height (cm) | 165.5 cm | 166.6 cm | 166.4 cm | 167.6 cm | 166.6 cm |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants | 45 Participants | 14 Participants | 14 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 44 Participants | 158 Participants | 36 Participants | 37 Participants | 41 Participants |
| Sex: Female, Male Female | 38 Participants | 140 Participants | 31 Participants | 37 Participants | 34 Participants |
| Sex: Female, Male Male | 14 Participants | 67 Participants | 20 Participants | 15 Participants | 18 Participants |
| Weight (kg) | 75.05 kg | 80.30 kg | 81.00 kg | 86.11 kg | 80.36 kg |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 52 | 1 / 51 | 0 / 53 | 0 / 50 |
| other Total, other adverse events | 26 / 52 | 35 / 51 | 23 / 53 | 27 / 50 |
| serious Total, serious adverse events | 1 / 52 | 1 / 51 | 1 / 53 | 0 / 50 |
Outcome results
Primary
Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs)
Percentage of participants with serious adverse events (SAEs) and new onset of chronic illness (NOCIs)
Time frame: 6 months after vaccination
Population: Safety population, defined as all participants exposed to study vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| VAX-24 Low Dose | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | Participants with at least 1 SAE | 1.9 Percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | Participants with at least 1 NOCI | 1.9 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | Participants with at least 1 NOCI | 2.0 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | Participants with at least 1 SAE | 2.0 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | Participants with at least 1 SAE | 1.9 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | Participants with at least 1 NOCI | 1.9 Percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | Participants with at least 1 SAE | 0.0 Percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs) | Participants with at least 1 NOCI | 0.0 Percentage of participants |
Primary
Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination
Solicited local reactions included redness/erythema, swelling/induration, and pain at injection site
Time frame: 7 days after vaccination
Population: Safety population, defined as all participants exposed to study vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Any solicited local AE (any grade) | 42.3 percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Pain (Local-any grade) | 38.5 percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Erythema (redness) at the injection site (any grade) | 3.8 percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Edema (swelling) at the injection site (any grade) | 5.8 percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Pain (Local-any grade) | 62.7 percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Erythema (redness) at the injection site (any grade) | 3.9 percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Edema (swelling) at the injection site (any grade) | 2.0 percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Any solicited local AE (any grade) | 62.7 percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Erythema (redness) at the injection site (any grade) | 3.8 percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Pain (Local-any grade) | 37.7 percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Edema (swelling) at the injection site (any grade) | 3.8 percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Any solicited local AE (any grade) | 37.7 percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Edema (swelling) at the injection site (any grade) | 6.0 percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Pain (Local-any grade) | 48.0 percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Any solicited local AE (any grade) | 48.0 percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Erythema (redness) at the injection site (any grade) | 10.0 percentage of participants |
Primary
Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination
Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain within 7 days of vaccination
Time frame: 7 days after vaccination
Population: Safety population, defined as all participants exposed to study vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Any solicited systemic AE (any grade) | 34.6 Percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Fever (any grade) | 0 Percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Fatigue (any grade) | 26.9 Percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Headache (any grade) | 17.3 Percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Muscle Pain (any grade) | 19.2 Percentage of participants |
| VAX-24 Low Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Joint pain (any grade) | 9.6 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Joint pain (any grade) | 11.8 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Headache (any grade) | 11.8 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Fatigue (any grade) | 31.4 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Muscle Pain (any grade) | 27.5 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Fever (any grade) | 0 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Any solicited systemic AE (any grade) | 41.2 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Fever (any grade) | 0 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Fatigue (any grade) | 15.1 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Joint pain (any grade) | 5.7 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Headache (any grade) | 11.3 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Muscle Pain (any grade) | 17.0 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Any solicited systemic AE (any grade) | 28.3 Percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Muscle Pain (any grade) | 32.0 Percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Fatigue (any grade) | 14.0 Percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Fever (any grade) | 0 Percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Any solicited systemic AE (any grade) | 44.0 Percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Joint pain (any grade) | 4.0 Percentage of participants |
| PCV20Group 4 | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination | Headache (any grade) | 16.0 Percentage of participants |
Primary
Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After Vaccination
Percentage of participants with at least one Treatment Emergent Adverse Event (unsolicited AEs and SAEs)
Time frame: 1 month after vaccination
Population: Safety population. defined as all participants exposed to study vaccine
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| VAX-24 Low Dose | Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After Vaccination | 11.5 Percentage of participants |
| VAX-24 Mid Dose | Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After Vaccination | 7.8 Percentage of participants |
| VAX-24 Mixed Dose | Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After Vaccination | 5.7 Percentage of participants |
| PCV20Group 4 | Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After Vaccination | 16.0 Percentage of participants |
Secondary
24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs)
The change from baseline to 1 month post-vaccination in the immune response directed against each of the 24 serotypes was evaluated by measuring IgG levels using an IgG multiplexed electrochemoluminescent assay (ECLA). Values below the lower limit of quantitation (LLOQ) were analyzed as 0.5\*LLOQ. Values above the upper limit of quantitation (ULOQ) were analyzed as 1\*ULOQ.
Time frame: 1 month after vaccination
Population: Immunogenicity evaluable population including all participants as treated.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 6B | 3.17 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 2 | 13.42 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 1 | 4.85 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 3 | 0.56 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 4 | 2.51 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 5 | 2.39 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 6A | 5.26 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 7F | 4.88 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 8 | 7.21 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 9N | 7.93 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 9V | 4.91 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 10A | 7.77 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 11A | 5.33 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 12F | 1.86 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 14 | 7.93 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 15B | 12.16 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 17F | 10.81 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 18C | 8.17 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 19A | 10.58 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 19F | 8.21 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 20B | 18.18 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 22F | 3.26 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 23F | 5.16 mcg/mL |
| VAX-24 Low Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 33F | 11.96 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 33F | 14.34 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 11A | 5.46 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 19F | 9.61 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 17F | 10.82 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 22F | 6.53 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 12F | 2.77 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 4 | 2.50 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 15B | 17.82 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 8 | 8.08 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 14 | 12.21 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 6A | 8.61 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 3 | 0.64 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 20B | 24.61 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 9N | 9.83 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 5 | 3.20 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 2 | 19.04 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 7F | 5.50 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 9V | 5.56 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 1 | 5.36 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 19A | 13.97 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 18C | 11.92 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 10A | 12.31 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 6B | 7.50 mcg/mL |
| VAX-24 Mid Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 23F | 9.10 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 9V | 7.63 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 6B | 5.92 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 7F | 7.67 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 8 | 5.53 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 9N | 8.32 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 20B | 19.51 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 10A | 9.48 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 11A | 5.73 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 12F | 2.07 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 22F | 4.14 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 14 | 10.41 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 15B | 13.82 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 33F | 13.24 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 17F | 10.78 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 18C | 15.03 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 23F | 7.10 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 19A | 13.37 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 1 | 4.13 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 2 | 9.20 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 3 | 0.85 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 4 | 2.24 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 5 | 2.03 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 19F | 11.51 mcg/mL |
| VAX-24 Mixed Dose | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 6A | 6.86 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 4 | 2.16 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 9V | 3.46 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 7F | 4.52 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 1 | 4.14 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 19F | 3.14 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 9N | 3.22 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 6B | 1.99 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 2 | 1.59 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 19A | 7.84 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 8 | 5.16 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 5 | 2.67 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 14 | 9.08 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 22F | 7.99 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 12F | 0.88 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 3 | 0.68 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 15B | 12.48 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 23F | 5.31 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 11A | 4.70 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 33F | 10.82 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 17F | 0.56 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 10A | 9.43 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 20B | 4.77 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 6A | 4.61 mcg/mL |
| PCV20Group 4 | 24 VAX-24 Pneumococcal Serotype-specific IgG Geometric Mean Concentration (GMCs) | 18C | 8.25 mcg/mL |
Secondary
VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs)
The change from baseline to 1 month post-vaccination in the immune response directed against each of the 24 serotypes was evaluated by measuring serotype-specific functional antibody responses with an opsonophagocytic (OPA) assay that assesses the functional capacity of pneumococcal antibodies.
Time frame: 1 month after vaccination
Population: Immunogenicity Evaluable Populations, defined as participants in the exposed population with no major protocol deviation that impacted immunogenicity assessment and provided evaluable serum sample results for baseline, the relevant post-vaccination time points, and within the required time frames.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6B | 1889.61 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 2 | 1224.83 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 3 | 252.56 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 4 | 1386.27 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 5 | 340.10 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6A | 1672.35 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 | 288.67 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 7F | 2738.72 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 8 | 1789.95 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9N | 7559.19 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9V | 927.63 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 10A | 2544.55 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 11A | 879.43 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 12F | 1060.55 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 14 | 1972.20 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 15B | 1964.60 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 17F | 2010.33 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 18C | 1553.59 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19A | 3608.79 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19F | 1211.40 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 20B | 6871.60 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 22F | 3326.80 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 23F | 808.78 Titer |
| VAX-24 Low Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 33F | 8681.95 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 33F | 11868.64 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 11A | 1068.11 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 4 | 1375.38 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 23F | 823.11 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 22F | 6107.92 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 12F | 1153.52 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 8 | 1970.88 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 17F | 2035.09 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6A | 3678.45 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 14 | 3253.68 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 3 | 311.14 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 15B | 1504.58 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 20B | 7368.09 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9N | 7451.59 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19F | 1305.32 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 2 | 1865.97 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 7F | 2884.67 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9V | 1601.84 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6B | 2736.64 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19A | 5805.66 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 | 284.55 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 10A | 2921.81 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 5 | 459.02 Titer |
| VAX-24 Mid Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 18C | 2237.89 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9V | 1858.57 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6B | 2827.09 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 7F | 3725.68 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 8 | 1450.17 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9N | 7295.23 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 20B | 6621.65 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19F | 1723.29 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 10A | 2484.44 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 11A | 1072.92 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 12F | 1233.96 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 22F | 4248.38 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 14 | 1607.64 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 15B | 1489.75 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 33F | 10621.27 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 17F | 1979.30 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 18C | 2894.88 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 23F | 1182.95 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 | 135.10 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 2 | 1060.68 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19A | 5124.99 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 3 | 350.55 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 4 | 1472.75 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 5 | 240.64 Titer |
| VAX-24 Mixed Dose | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6A | 2492.54 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 23F | 630.71 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 20B | 75.74 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 7F | 3189.78 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 | 182.60 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9V | 972.10 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9N | 1673.49 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6A | 1877.87 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 2 | 81.26 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 5 | 390.30 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 8 | 1498.73 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19F | 854.85 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 3 | 342.86 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 22F | 8596.62 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 14 | 2491.35 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19A | 3808.09 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 15B | 1759.25 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 33F | 9994.41 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 12F | 718.93 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6B | 2132.92 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 17F | 267.63 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 11A | 814.61 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 10A | 2490.76 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 4 | 1031.62 Titer |
| PCV20Group 4 | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 18C | 1327.56 Titer |